Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
6.50
-0.20 (-2.99%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Anbio Biotechnology Revenue
Anbio Biotechnology had revenue of $5.85M in the half year ending June 30, 2024, a decrease of -67.21%. This brings the company's revenue in the last twelve months to $9.50M, up 8.43% year-over-year. In the year 2023, Anbio Biotechnology had annual revenue of $6.71M, down -71.49%.
Revenue (ttm)
$9.50M
Revenue Growth
+8.43%
P/S Ratio
29.06
Revenue / Employee
$351,928
Employees
27
Market Cap
286.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | 19.12M | 431.67% |
| Dec 31, 2021 | 4.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNNNN News
- 2 months ago - U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
- 2 months ago - Anbio Biotechnology Announces Closing of Initial Public Offering - GlobeNewsWire
- 2 months ago - Anbio Biotechnology Announces Pricing of Initial Public Offering - GlobeNewsWire
- 4 months ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 4 months ago - Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
- 4 months ago - Anbio Biotechnology IPO Registration Document (F-1) - SEC